However, given that the dynamic expression of tumor PD-L1 is lower than that of exosome PD-L1 and the detection of tumor PD-L1 requires invasive tumor biopsies, exosome PD-L1 may be a promising blood-based biomarker. This evidence concerns the gene CD274 and neoplasm.